1、KEYNOTE 091 临床研究 PD-L1≥50% 高表达人群结果的失利打破了我们常规认知,PD-L1 表达是否能成为围手术期分层指标成为很大的疑问。 2、IMpower010 获益在 PD-L1 阳性特别是 ≥50% 的患者中更为明显,而在 PD-L1 1%-49...
2023年ASCO大会上,也将有多项早期肺癌领域重磅级研究亮相,其中,KEYNOTE-091、CheckMate-816、IMpower010三项关键研究也将公布最新结果。 KEYNOTE-091:帕博利珠单抗用于早期NSCLC辅助化疗后的辅助治疗 背景:III期PEARLS/KEYNOTE-091研究第二次中期...
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocar...
At an earlier interim analysis, the trial’s other dual primary endpoint, progression-free survival (PFS) was tested and showed an improvement in the KEYTRUDA arm compared to chemotherapy alone, but these results did not reach statistical significance. In KEYNOTE-641 and KEYNOTE-789, the ...
Health care professionals may find clinical trial results for KEYNOTE-006 in patients with advanced melanoma.
Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. 6005 Background: Pembrolizumab (pembro) showed modest clinical activity in patients (pts) with recurrent advanced ovarian cancer (AOC) after a median follow-up of 16.9 mo in an interim an...
3月17日,ESMO Virtual Plenary Resources发布了PEARLS/KEYNOTE-091[1]研究结果。研究评估了帕博利珠单抗作为辅助治疗在完全切除的早期非小细胞肺癌(NSCLC) 患者中的疗效。 NSCLC围术期免疫治疗现状 NADIM——围术期首发,彰显免疫实力 NADIM研究是较早启动的免疫联合化疗的新辅助研究之一,其在2018年WCLC大会上公布的研...
4. O'Brien M, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274-1286. ...
[6] O'Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-ⅢA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 2022;23:1274-86. ...
[15]O'Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274-1286...